One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients

BACKGROUND: Results of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of the randomized CAPSID trial are to assess long-term outcome and disease burden i...

Descripción completa

Detalles Bibliográficos
Autores principales: Körper, Sixten, Grüner, Beate, Zickler, Daniel, Wiesmann, Thomas, Wuchter, Patrick, Blasczyk, Rainer, Zacharowski, Kai, Spieth, Peter, Tonn, Torsten, Rosenberger, Peter, Paul, Gregor, Pilch, Jan, Schwäble, Joachim, Bakchoul, Tamam, Thiele, Thomas, Knörlein, Julian, Dollinger, Matthias M., Krebs, Jörg, Bentz, Martin, Corman, Victor M., Kilalic, Dzenan, Schmidtke-Schrezenmeier, Gerlinde, Lepper, Philipp M., Ernst, Lucas, Wulf, Hinnerk, Ulrich, Alexandra, Weiss, Manfred, Kruse, Jan Matthias, Burkhardt, Thomas, Müller, Rebecca, Klüter, Harald, Schmidt, Michael, Jahrsdörfer, Bernd, Lotfi, Ramin, Rojewski, Markus, Appl, Thomas, Mayer, Benjamin, Schnecko, Philipp, Seifried, Erhard, Schrezenmeier, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753994/
https://www.ncbi.nlm.nih.gov/pubmed/36326824
http://dx.doi.org/10.1172/JCI163657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753994/
https://www.ncbi.nlm.nih.gov/pubmed/36326824
http://dx.doi.org/10.1172/JCI163657

Ejemplares similares